OPP001 📄 Overview An AI-powered SaMD that predicts individual patient response (e.g., expected weight loss, HbA1c reduction) and potential side effect profiles (e.g., nausea, vomiting, constipation) based on a comprehensive set of patient data (genomics, metabolomics, lifestyle, existing comorbidities, historical treatment data). This tool would guide clinicians in selecting the most appropriate GLP-1 drug, initial dosing strategy, and proactive side effect management plan. Key technologies: 👤 Target users: 👍 Benefits Optimized patient selection • Reduced trial-and-error in treatment • Improved patient satisfaction and adherence due to fewer side effects • Better clinical outcomes (weight loss, glycemic control) Use bullets or new lines. 👎 Challenges Data interoperability across diverse sources • Validation with diverse patient populations • Regulatory clearance as a SaMD with clinical decision support claims • Ensuring explainability and mitigating algorithmic bias 📋 Regulatory & Validation Likely Class II SaMD (decision support) • Requires rigorous clinical validation and cybersecurity • Transparency on algorithm logic for clinicians is crucial